Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-10-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司地中海贫血基因检测产品获得沙特阿拉伯食品药品管理局批准上市的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the approval of a gene detection product by the Saudi Food & Drug Authority (SFDA) for market launch. It details the product information, market context, and potential impact on the company. There is no financial data, no mention of a report or filing, and the document is relatively short (1630 characters). It is clearly an announcement about a regulatory approval for a product, not a financial report or management update. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-10-08 Chinese
关于实际控制人兼董事长增持公司股份计划的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the plan of the company's actual controller and chairman to increase his shareholding in the company. It details the planned share purchase amount, period, methods, and related compliance information. There are no financial statements, earnings data, or report contents. The document is about a director's personal share transactions (planned increase in holdings). This fits the definition of Director's Dealing (DIRS). The document length is short and focused on shareholding changes by a director, not a full report or announcement of a report publication.
2021-09-28 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2021年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2021年半年度跟踪报告' which translates to '2021 Half-Year Tracking Report' for Shenzhen BGI Genomics Co., Ltd. It is issued by CITIC Securities Co., Ltd. as the sponsor institution. The content includes detailed oversight and supervision activities, compliance with regulatory requirements, company and shareholder commitments, and other related matters during the half-year period. The document contains substantive information about the company's governance, compliance, and operational status during the half-year period, which aligns with the characteristics of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification but a comprehensive report covering a period shorter than a full fiscal year with substantive content. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2021
2021-09-13 Chinese
关于持股5%以上股东减持计划期限届满暨实施情况的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the expiration of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the methods of reduction, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but focuses on shareholding changes by a major shareholder. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2021-09-10 Chinese
关于公司高级管理人员辞任的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel (the vice general manager) of the company. It details the resignation, effective date, shareholding information, and compliance with relevant regulations post-resignation. There is no financial data, no mention of a report or meeting, and it focuses solely on management changes. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2021-09-03 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2021年半年度募集资金存放与实际使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2021年半年度募集资金存放与实际使用情况的专项核查报告" which translates to a "Special Inspection Report on the Deposit and Actual Use of Raised Funds for the Half Year 2021". It is issued by CITIC Securities as the sponsor institution for Shenzhen BGI Genomics Co., Ltd. The content details the amount of funds raised, their deposit, management, and actual usage during the half-year period ending June 30, 2021. It includes detailed financial figures, bank account information, agreements related to fund supervision, and verification by an accounting firm. The document is a specialized audit or verification report focusing on the use of raised funds, not a full annual or interim financial report. It is not an announcement or a brief summary but a detailed report on a specific regulatory compliance aspect related to fundraising. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to regulatory requirements, excluding full annual or interim reports. Therefore, the document should be classified as AR with high confidence. H1 2021
2021-08-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.